Virtu Financial’s Atea Pharmaceuticals AVIR Stock Holding History

Virtu Financial’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,030	Closed	-$183K	–	1601
2026 Q1	$183K	Buy	+34,030	New	+$156K	0.01%	1048
2024 Q4	–	Sell	-29,491	Closed	-$99K	–	1540
2024 Q3	$99K	Buy	+29,491	New	+$107K	0.01%	911
2022 Q4	–	Sell	-30,693	Closed	-$175K	–	1591
2022 Q3	$175K	Buy	+30,693	New	+$235K	0.02%	914
2021 Q4	–	Sell	-26,522	Closed	-$930K	–	1701
2021 Q3	$930K	Buy	+26,522	New	+$736K	0.08%	254
2021 Q2	–	Sell	-5,626	Closed	-$347K	–	1500
2021 Q1	$347K	Buy	+5,626	New	+$380K	0.02%	724

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtu Financial's AVIR Position: Q2 2026 in Review

Virtu Financial sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 34,030 shares — an estimated $183K sold.

Virtu Financial first reported a position in AVIR in Q1 2021 and held it in 5 quarters. The position peaked at $930K in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Virtu Financial reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 34,030 Atea Pharmaceuticals shares in Q2 2026, an estimated $183K.
Virtu Financial first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Virtu Financial's Atea Pharmaceuticals position peaked at $930K in Q3 2021.
124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.